newscontact us

CESCA THERAPEUTICS ANNOUNCES CLOSING OF $5 MILLION REVOLVING LINE OF CREDIT

RANCHO CORDOVA, CA, March 13, 2017 – Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care autologous cell-based therapies, today announced that it has closed a revolving line of credit (“RLOC”) with Boyalife Investment Fund II, Inc. The non-collaterized RLOC is for a term of five years and is generally drawable at Cesca’s discretion. Boyalife Investment Fund II, Inc. is a wholly owned subsidiary of Boyalife Group Inc.,which is a company owned and controlled by the Company’s Interim Chief Executive Officer and Chairman of the Board. Cesca also announced that it has set-up a wholly-owned subsidiary, ThermoGenesis Corp, to separately own and operate, and thereby strengthen its device business. The clinical development activities will remain with Cesca, the parent company…(more)